Amgen is set to acquire Otezla (apremilast) from Celgene, the companies have announced.
The acquisition is in connection with its previously announced merger with
The company will also receive certain related assets and liabilities for
Amgen has announced that upon the gaining of Otezla, they can provide "at least low double-digit" Otezla sales growth, on average over the next five years and "accelerate the company’s near- and long-term revenue growth."
The acquisition of Otezla offers a “unique opportunity for
He continued, "We will take advantage of our 20 years of experience in inflammatory disease to realise the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions."
The company said that the “closing of the acquisition is contingent on
"Otezla represents an exciting opportunity to strengthen
"We are excited about the opportunity that Otezla represents for
The transaction is expected to close by the end of 2019.